ATE294804T1 - Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer - Google Patents

Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer

Info

Publication number
ATE294804T1
ATE294804T1 AT01938263T AT01938263T ATE294804T1 AT E294804 T1 ATE294804 T1 AT E294804T1 AT 01938263 T AT01938263 T AT 01938263T AT 01938263 T AT01938263 T AT 01938263T AT E294804 T1 ATE294804 T1 AT E294804T1
Authority
AT
Austria
Prior art keywords
annellated
farnesyl
pharmaceutical composition
composition containing
transferase inhibiting
Prior art date
Application number
AT01938263T
Other languages
German (de)
English (en)
Inventor
Marc Gaston Venet
Patrick Rene Angibaud
David William End
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE294804T1 publication Critical patent/ATE294804T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01938263T 2000-06-22 2001-06-13 Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer ATE294804T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (1)

Publication Number Publication Date
ATE294804T1 true ATE294804T1 (de) 2005-05-15

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01938263T ATE294804T1 (de) 2000-06-22 2001-06-13 Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer

Country Status (33)

Country Link
US (3) US20030114471A1 (enExample)
EP (1) EP1296984B1 (enExample)
JP (1) JP4919575B2 (enExample)
KR (2) KR100831940B1 (enExample)
CN (1) CN1207296C (enExample)
AR (1) AR030704A1 (enExample)
AT (1) ATE294804T1 (enExample)
AU (3) AU2001263962B2 (enExample)
BG (1) BG65894B1 (enExample)
BR (1) BRPI0111743B8 (enExample)
CA (1) CA2410232C (enExample)
CZ (1) CZ295278B6 (enExample)
DE (1) DE60110592T2 (enExample)
EA (1) EA005065B1 (enExample)
EE (1) EE04966B1 (enExample)
EG (1) EG24180A (enExample)
ES (1) ES2241830T3 (enExample)
HR (1) HRP20020989B1 (enExample)
HU (1) HU229095B1 (enExample)
IL (2) IL153560A0 (enExample)
IS (1) IS2596B (enExample)
JO (1) JO2361B1 (enExample)
MX (1) MXPA02012845A (enExample)
MY (1) MY127734A (enExample)
NO (1) NO324494B1 (enExample)
NZ (1) NZ522481A (enExample)
PA (1) PA8519501A1 (enExample)
PL (1) PL209521B1 (enExample)
SA (1) SA01220349B1 (enExample)
SK (1) SK285699B6 (enExample)
UA (1) UA73572C2 (enExample)
WO (1) WO2001098302A1 (enExample)
ZA (1) ZA200210305B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
CA2481480C (en) 2002-04-15 2011-04-12 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69635966T2 (de) * 1995-12-08 2006-11-30 Janssen Pharmaceutica N.V. (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
SK146199A3 (en) * 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
IL133212A (en) 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ID26987A (id) * 1998-07-06 2001-02-22 Janssen Pharmaceutica Nv Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
KR20010072991A (ko) * 1998-08-27 2001-07-31 실버스타인 아써 에이. 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체
PT1140935E (pt) * 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP2003523381A (ja) 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
ATE409189T1 (de) 2000-09-25 2008-10-15 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate

Also Published As

Publication number Publication date
HK1058363A1 (en) 2004-05-14
EE200200695A (et) 2004-06-15
CZ295278B6 (cs) 2005-06-15
EA005065B1 (ru) 2004-10-28
AU2001263962B2 (en) 2006-07-20
CA2410232C (en) 2008-10-07
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
BRPI0111743B8 (pt) 2021-05-25
US8318753B2 (en) 2012-11-27
EE04966B1 (et) 2008-02-15
HUP0300872A3 (en) 2004-11-29
CA2410232A1 (en) 2001-12-27
SK502003A3 (en) 2003-05-02
BR0111743A (pt) 2003-07-08
JP4919575B2 (ja) 2012-04-18
NO20026032L (no) 2002-12-16
ES2241830T3 (es) 2005-11-01
HRP20020989B1 (hr) 2011-05-31
AU2006220405A1 (en) 2006-10-12
BRPI0111743B1 (pt) 2019-03-26
HUP0300872A2 (hu) 2003-07-28
BG65894B1 (bg) 2010-04-30
JO2361B1 (en) 2006-12-12
SA01220349B1 (ar) 2007-01-23
PL358918A1 (en) 2004-08-23
KR100846370B1 (ko) 2008-07-15
EG24180A (en) 2008-09-28
NO324494B1 (no) 2007-10-29
HRP20020989A2 (en) 2005-02-28
CZ2003114A3 (cs) 2003-05-14
IS6590A (is) 2002-10-25
CN1437601A (zh) 2003-08-20
NO20026032D0 (no) 2002-12-16
AR030704A1 (es) 2003-09-03
PA8519501A1 (es) 2002-08-29
PL209521B1 (pl) 2011-09-30
EA200300048A1 (ru) 2003-04-24
KR20070121847A (ko) 2007-12-27
NZ522481A (en) 2004-09-24
DE60110592T2 (de) 2006-01-19
AU6396201A (en) 2002-01-02
BG107310A (bg) 2003-07-31
HU229095B1 (en) 2013-07-29
US20030114471A1 (en) 2003-06-19
UA73572C2 (en) 2005-08-15
MXPA02012845A (es) 2003-05-15
US20070259902A1 (en) 2007-11-08
KR20030009463A (ko) 2003-01-29
KR100831940B1 (ko) 2008-05-23
IS2596B (is) 2010-03-15
CN1207296C (zh) 2005-06-22
EP1296984B1 (en) 2005-05-04
US8329714B2 (en) 2012-12-11
EP1296984A1 (en) 2003-04-02
IL153560A0 (en) 2003-07-06
AU2006220405B2 (en) 2009-05-21
ZA200210305B (en) 2004-03-19
WO2001098302A1 (en) 2001-12-27
MY127734A (en) 2006-12-29
US20080114009A1 (en) 2008-05-15
IL153560A (en) 2011-06-30
SK285699B6 (sk) 2007-06-07

Similar Documents

Publication Publication Date Title
EG24357A (en) New Pharmaceutical composition
DE50014244D1 (de) Pharmazeutische tramadolsalze
ATE468324T1 (de) Pharmazeutische zusammensetzung
FI991485L (fi) Uusi farmaseuttinen koostumus
DK1251857T3 (da) Paranteralt farmaceutisk præparat indeholdende et biphosphonat
DE69833464D1 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
DE69940904D1 (de) Pharmazeutische zusammensetzung enthaltend epothilone
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
HUP0400644A3 (en) Pharmaceutical compositions containing aspirin
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
FI5176U1 (fi) Sitalopraamia sisältävä farmaseuttinen koostumus
GB0031084D0 (en) Pharmaceutical compounds
NO20014926L (no) Farmasöytiske forbindelser
DE60129238D1 (de) Pharmazeutische zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
DK1317256T3 (da) Farmaceutisk sammensætning havende en modificeret bærer
NO20026032L (no) Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
EP1124557A4 (en) Pharmaceutical composition
GB0019272D0 (en) Pharmaceutical compounds
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
GB0024318D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296984

Country of ref document: EP